Acuamark Diagnostics is pleased to announce Giulia Kennedy, Ph.D., has joined our board of directors. Dr. Kennedy brings more than two decades of experience developing novel diagnostic technologies, most recently as global chief scientific officer and chief medical officer at Veracyte, a cancer genetics company.
At Veracyte, she oversaw a worldwide team of research and development, medical affairs, data science, and clinical affairs professionals to fuel research and the development of the company’s genomic and other diagnostic tests.
Dr. Kennedy's diverse experience and expertise in company building and the development and commercialization of diagnostic products will be essential in this phase of Acuamark's growth.
We welcome Dr. Kennedy, and we look forward to her contributions to the company's growth and success. With her addition to our board of directors, Acuamark aims to further advance our mission to make frequent, recurrent sequential cancer monitoring the standard of primary care.
To learn more about the recent appointment of Dr. Giulia Kennedy, please visit the official press release.
Contact us at
Contact:
Acuamark Diagnostics, Inc.
101 Avenue Of the Americas, Fl 3, JLabs
New York, NY, 10013
USA
